Canada approves 1st generic semaglutide shot for weight loss

Health Canada has authorized the first generic version of a semaglutide injection specifically for weight management. The product, named Svemia, is manufactured by the Canadian pharmaceutical company Apotex and is bioequivalent to Wegovy, a popular brand-name drug produced by Denmark's Novo Nordisk.

Svemia is indicated for once-weekly use in individuals aged 12 and older as a supplement to a reduced-calorie diet and increased physical activity for chronic weight management. This marks a significant step in making weight-loss treatments more accessible.

This approval follows previous authorizations by Health Canada for two other generic semaglutide products earlier this year. However, those were specifically for the treatment of Type 2 diabetes in adults. The generic versions of Novo Nordisk's Ozempic, also used for diabetes, were developed by India-based Dr. Reddy's Laboratories and Apotex.

Health Canada is currently reviewing six additional submissions for generic semaglutide from various companies, indicating a growing market for these medications. Further decisions on these submissions are anticipated in the coming weeks and months.